Introduction
Haematopoietic SCT (HSCT) represents a curative option for many haematological malignancies. 1 A HLA-identical sibling is considered the best HSC donor; however, the search for an unrelated donor is currently performed when a patient lacks such an HLA-matched sibling. Searching algorithms aim at finding the optimal match between the patient and the potential donor. 2 As the '10/10 matched' (that is, high-resolution identity at loci HLA-A, -B, -C, -DRB1 and -DQB1) donor is not always available, some extent of HLA mismatch (Mm) can be accepted; however, there is still some controversy about the precise impact of HLA mismatching on HSCT outcomes, because published reports indicate discordant results about the relative importance of loci involved. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] A recent study by Lee et al. 3 indicated that both class I and class II Mms affect survival, suggesting that each HLA Mm is associated with an additional unadjusted survival impairment of 9-10%. The same study did not find a significant role played by HLA-DP or -DQ on survival. Other analyses reported a higher risk of graft failure correlated with class I Mms and a superior rate of mortality in the presence of two or more Mms (regardless of loci involved), whereas one Mm did not confer survival impairment. 5, 14 Single Mms at HLA-B or -C seem to be better tolerated than those at HLA-A or -DRB1 in American patients, 3 whereas in Japanese patients the presence of HLA-A and -B Mm significantly reduced survival and Mm at HLA-C or -DRB1/DQB1 did not. 12 The relative importance of antigenic (detected by serological or low-resolution typing) or allelic (high resolution) Mms has also been studied, and the results are controversial because the studies report both an equivalent 3, 11 and a different 7 effect on outcome. Finally, a recent analysis provided by Kawase et al. 4 identified 16 significant highrisk HLA Mm combinations for severe acute GVHD (aGVHD), whereas the selection of a cross-reactive groupcompatible donor does not seem to improve transplant outcome. 9 This study was designed to assess the role of patientdonor HLA matching on the outcomes of unrelated HSCTs performed for haematological malignancies in 805 adult patients in Italy.
Patients and methods

Patients and treatments
A total of 805 patients aged 18 years or more who received HSCTs from unrelated donors in Italy from 1 January 1999 to 30 June 2006 were included in the analysis (Table 1) . Eligible diagnoses were ALL, AML, CML, myelodysplastic syndrome, myeloproliferative syndromes other than CML, secondary acute leukaemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma and CLL. Informed consent was obtained from each transplantation centre.
All clinical data were obtained from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) registry, and all patient-donor typing results were collected from the Italian Bone Marrow Donor Registry (IBMDR). 15 According to disease status at HSCT, patients were categorized into three groups: CML in first chronic phase ('CML-CP1'), acute leukaemia in first complete remission ('early') and all other diseases ('advanced'). HSCT conditioning regimens were both myeloablative and reduced intensity, according to local or cooperative protocols. Induction therapy and HSCT indication was decided by treating physicians in each centre, according to the risk/benefit profile based on the most updated knowledge at the time of therapy. Information on in vivo T-cell depletion was collected; aGVHD prophylaxis was mostly performed with CYA and MTX.
HLA typing and HSCT All Mms were classified according to the loci involved and according to whether they were detected at low-or highresolution level.
Originally, only low-resolution typing of loci A, B and high-resolution at locus DRB1 were used to screen potential donors, and the matching at these three loci was the minimum requested for performing HSCT; 16 in the absence of such a '6/6 matched' donor, some exceptions were allowed; therefore, transplants using a '5/6 matched' donor were performed.
As the degree of typing was heterogeneous among patient-donor pairs, this analysis includes only 10/10 high-resolution typed pairs, to exclude any confounding effect eventually played by the match at loci not fully typed.
Clinical end point definitions
Overall survival (OS), non-relapse mortality, aGVHD and engraftment were defined according to European Group for Blood and Marrow Transplantation (EBMT) criteria; 17 relapse-related death is defined as death because of relapse after HSCT, irrespective of further treatment performed for relapse. All outcomes were evaluated from the day of stem cell infusion. Grading of aGVHD was performed according to current criteria. 18 
Statistical analysis
Continuous variables were expressed as median (range), whereas categorical ones were expressed as proportions and percentages. Probabilities of OS were calculated using the Kaplan-Meier estimator 19 and survival curves were compared using the logrank test. 20 Univariate analysis tested any association between HLA matching and the outcome of interest. Analysis for each outcome was performed comparing the pairs mismatched at a specific locus with HLA 10/10 matched pairs, thus avoiding any interference played by Mms at other loci. This approach has been successfully used in earlier studies. 3, 11 Pairs with two Mms were grouped together irrespective of the loci involved; pairs with three and four Mms were grouped together. A heterogeneity test was performed between pairs with one antigenic or allelic Mm to verify whether they had a different impact on survival; it was performed within pairs with a single Mm between the different loci involved in Mm. Multivariate models were built after the addition of all non-HLA factors that were significantly associated with outcome in univariate analysis. Po0.20 and Po0.05 were considered as cutoff values in univariate and multivariate analyses, respectively. Both analyses were performed using Cox regression 21 for OS, relapse-related death and nonrelapse mortality and logistic regression for aGVHD and engraftment. Non-HLA factors included: donor's gender, age (continuous variable) and CMV status; patient's gender, age (continuous variable), CMV status; year of transplantation (continuous variable), use of anti-thymocyte globulin, disease group (advanced vs early vs CML-CP1), source of HSCs (PBSCs vs BM), conditioning regimen (myeloablative vs reduced intensity), use of TBIbased conditioning. Centre effect (440 HSCT vs p40) was tested and was NS. Disease status at transplant and use of anti-thymocyte globulin were tested for interaction with HLA matching. No significant interactions were identified.
Results
Patient-donor pairs
A total of 805 pairs typed at high resolution for HLA-A, -B, -C, DRB1 and -DQB1 were included in the analysis. Overall, three quarters of patients (611 out of 805, 75%) received HSCT for an advanced-stage haematological malignancy; of these, 205 were lymphoid malignancies other than ALL: 76 non-Hodgkin's lymphoma, 63 multiple myeloma, 52 Hodgkin's lymphoma and 14 CLL. Median follow-up was 25 months (range: 3-85). Patients' and donors' characteristics are shown in Table 1 .
HSCT outcome All pairs were classified according to the numbers of Mms and loci involved. Heterogeneity tests disclosed significant differences in the probability of OS between pairs with a single low-resolution (antigenic) or high-resolution (allelic) Mms; therefore, they were considered equivalent and grouped together in all analyses.
Overall survival A slight but not statistically significant survival difference emerged from the analysis between pairs with a single Mm compared with 10/10 matched pairs. This is true for any locus analyzed separately and also after grouping single Mm pairs together, as no heterogeneity exists between loci A, B, C and DQB1 (data not shown). Multivariate hazard ratio of OS was 1.12 (95% CI ¼ 0.90-1.40, P ¼ 0.31) for single Mm compared with 10/10 matched pairs; a higher mortality risk was observed when the number of total Mms is two or more (HR ¼ 1.42, 95% CI ¼ 1.08-1.87, P ¼ 0.01, Table 2 ). Non-HLA factors significantly associated with survival were: patient's age at HSCT, donor gender, year of transplantation, disease status at HSCT, conditioning regimen (Table 3) . Survival curves according to HLA matching are shown in Figure 1a . Although interaction test between one HLA Mm and disease status at HSCT did not yield a statistically significant association for OS (P ¼ 0.12), we observed a greater effect played by a single Mm in Table 2 Adjusted hazard ratios of HSCT outcomes according to total number of HLA Mms (Table 2) ; however, heterogeneity tests showed no significant difference between loci DQB1 vs A, B or C (P ¼ 0.45). Other factors significantly associated with graft failure were donor's age, use of anti-thymocyte globulin and infusion of BM stem cells.
Acute GVHD grade 2-4
Overall rates of aGVHD grades 2-4 were 27, 40 and 39% for 10/10, 9/10 and p8/10 matched pairs. Incidence of aGVHD grades 3-4 were 9, 21 and 16%, respectively. Testing for HLA matching and occurrence of aGVHD resulted in a higher risk for pairs with two or more Mms (HR ¼ 1.68, 95% CI ¼ 1.05-2.69, P ¼ 0.03). Among pairs with a single Mm, only locus B resulted in a significant association with a higher risk of grades II-IV aGVHD (HR ¼ 2.25, 95% CI ¼ 1.10-4.61, P ¼ 0.03); in addition, no significant heterogeneity exists between loci B vs A, C or DQB1. Other significant non-HLA factors were: donor's age, patient's CMV status and myeloablative conditioning regimen.
Relapse-related death
No association was present between HLA matching and death because of relapse; therefore, no multivariate model was created for this end point.
Non-relapse mortality
Similar to survival analysis, no significant differences in non-relapse mortality were observed between pairs with one Mm compared with 10/10 matched ones. A significantly higher HR is associated with two or more Mms (Table 2 ). Other significant non-HLA factors present in the multivariate model were: donor's gender, patient's age at 
Discussion
In this study, we evaluated the impact of patient-donor HLA compatibility on the HSCT outcome of a large number of adult patients mostly receiving in vivo T-cell depleted allografts. Two levels of information emerge from the analysis. First, the relative value of low-resolution Mm seemed to be similar to that of high-resolution Mm, as no difference of HSCT outcome emerged when a single low-resolution Mm was compared with a high-resolution one. Studies published earlier indicate conflicting results; in fact, both equivalent 3, 11 and different 7 effects on outcome were reported; our results suggest that both low-and highresolution Mms should be considered equivalent in the search for the optimal donor-patient HLA matching at present. However, we cannot exclude that we did not find any statistical difference because of the relatively small numbers (a total of 171 vs 109 pairs with single lowresolution and high-resolution Mm, respectively).
Second, the presence of one or more Mms was associated with impaired survival as compared with 10/10 matched pairs, both in unadjusted and adjusted models ( Table 2 ). The predictive role of one single Mm was different in early as compared with advanced disease. In fact, in the subset of advanced disease, the choice of a one-Mm donor led to survival rates similar to 10/10 matched pairs in the same group (Figure 1c) , with 2-year survival estimates of 40 and 39%, respectively. On the other hand, 2-year OS was 63 and 54% for those with a 10/10 matched and 9/10 matched donor, respectively, among patients with early disease. This is probably explained by the fact that disease status at HSCT represents the strongest predictor of survival, and that HLA matching acquires a smaller impact on prognosis in advanced patients. Interestingly, our registry reported a higher number of lymphoproliferative diseases compared with other studies (here 205 out of 805 patients, 25%), and an analysis of this subgroup revealed that no effect on outcome is played by HLA matching (data not shown). Although the relatively small number of these cases and the retrospective nature of the subgroup analysis do not allow us to draw definite conclusions, this could partially explain why we did not detect a significant impairment of survival played by a single Mm overall. Other relevant differences from reported large analyses 3, 12 are the wider use of antithymocyte globulin (64% of patients in our series) and the higher rate of RIC transplants, together with a lesser extent of TBI use, factors all known to affect GVHD occurrence and survival. It is worth noting that all patient-donor pairs on this series were high-resolution matched at locus DRB1, different from most of the published studies: for this reason, no comparisons regarding this locus can be made.
Our findings confirm that the best matching for adult patients with acute leukaemia in first CR undergoing HSCT from unrelated donor is the 10/10 allele-matched; however, since a single patient-donor HLA Mm did not significantly affect survival of patients with advanced disease (including lymphoma), a 9/10-matched donor could be suitable for these patients. Even in the presence of one or multiple HLA Mms, the survival of early patients seems to be superior compared with that of advanced patients, showing that performing HSCT earlier in the course of the disease could improve patients' prognosis and that when a clinical indication for transplantation exists, the lack of a 10/10 matched donor should not preclude HSCT and the choice of a partially mismatched donor is warranted.
In conclusion, this study adds useful information about the role of HLA matching on the outcome of adult patients undergoing HSCT from a unrelated donor, thus helping physicians facing the search of a suitable donor for a haematological malignancy; it could also represent the basis for new emerging studies, possibly providing HLAmatching algorithms and/or new antigens that better correlate with prognosis and more precisely define the association with HSCT outcomes. 4, 9, [22] [23] [24] [25] [26] 
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